Antidiabetic compounds, any
| Zeile 5: | Zeile 5: | ||
{{tp|p=32313883|t=2020. Inhaled biguanides and mTOR inhibition for influenza and coronavirus (Review) |pdf=|usr=}} | {{tp|p=32313883|t=2020. Inhaled biguanides and mTOR inhibition for influenza and coronavirus (Review) |pdf=|usr=}} | ||
{{tp|p=32347974|t=2020. Metformin and COVID-19: A novel deal of an Old Drug |pdf=|usr=}} | {{tp|p=32347974|t=2020. Metformin and COVID-19: A novel deal of an Old Drug |pdf=|usr=}} | ||
| + | |||
| + | {{tp|p=32446796|t=2020. Metformin, neutrophils and COVID-19 infection.|pdf=|usr=008}} | ||
| + | |||
| + | {{tp|p=32360697|t=2020. Metformin in COVID-19: A possible role beyond diabetes.|pdf=|usr=008}} | ||
| + | {{tp|p=32339534|t=2020. COVID-19 and diabetes: Is metformin a friend or foe?|pdf=|usr=008}} | ||
| + | |||
'''DPP4''' | '''DPP4''' | ||
| Zeile 16: | Zeile 22: | ||
{{tp|p=32336007|t=2020. DPP4 inhibition: preventing SARS-CoV-2 infection and/or progression of COVID-19?|pdf=|usr=}} | {{tp|p=32336007|t=2020. DPP4 inhibition: preventing SARS-CoV-2 infection and/or progression of COVID-19?|pdf=|usr=}} | ||
{{tp|p=32224164|t=2020. COVID-19 and diabetes: Can DPP4 inhibition play a role?|pdf=|usr=}} | {{tp|p=32224164|t=2020. COVID-19 and diabetes: Can DPP4 inhibition play a role?|pdf=|usr=}} | ||
| + | {{tp|p=32335097|t=2020. SARS-CoV-2 and DPP4 inhibition: Is it time to pray for Janus Bifrons?|pdf=|usr=008}} | ||
| + | {{tp|p=32416120|t=2020. Is DPP4 inhibition a comrade or adversary in COVID-19 infection.|pdf=|usr=008}} | ||
| + | |||
'''SGLT2''' | '''SGLT2''' | ||
{{tp|p=32335366|t=2020. Can dapagliflozin have a protective effect against COVID-19 infection? A hypothesis |pdf=|usr=}} | {{tp|p=32335366|t=2020. Can dapagliflozin have a protective effect against COVID-19 infection? A hypothesis |pdf=|usr=}} | ||
| + | {{tp|p=32447736|t=2020. Lack of Efficacy of SGLT2-i in Severe Pneumonia Related to Novel Coronavirus (nCoV) Infection: No Little Help from Our Friends.|pdf=|usr=008}} | ||
| + | |||
'''PPAR''' | '''PPAR''' | ||
{{tp|p=32344313|t=ä. Can pioglitazone be potentially useful therapeutically in treating patients with covid-19?|pdf=|usr=}} | {{tp|p=32344313|t=ä. Can pioglitazone be potentially useful therapeutically in treating patients with covid-19?|pdf=|usr=}} | ||
{{tp|p=32365556|t=2020. Pharmacological (or Synthetic) and Nutritional Agonists of PPAR-gamma as Candidates for Cytokine Storm Modulation in COVID-19 Disease |pdf=|usr=}} | {{tp|p=32365556|t=2020. Pharmacological (or Synthetic) and Nutritional Agonists of PPAR-gamma as Candidates for Cytokine Storm Modulation in COVID-19 Disease |pdf=|usr=}} | ||
| + | ---- | ||
| + | |||
| + | {{tp|p=32334392|t=2020. Enhancing immunity in viral infections, with special emphasis on COVID-19: A review.|pdf=|usr=008}} | ||
| + | |||
| + | {{tp|p=32234504|t=2020. COVID-19, diabetes mellitus and ACE2: The conundrum.|pdf=|usr=008}} | ||
Version vom 27. Juni 2020, 20:42 Uhr
32456064 2020. Potential Benefits and Harms of Novel Antidiabetic Drugs During COVID-19 Crisis.
32382358 ä. COVID-19 and Diabetes Mellitus: May Old Anti-diabetic Agents Become the New Philosopher?s Stone?
Metformin
32313883 2020. Inhaled biguanides and mTOR inhibition for influenza and coronavirus (Review)
32347974 2020. Metformin and COVID-19: A novel deal of an Old Drug
32446796 2020. Metformin, neutrophils and COVID-19 infection.
32360697 2020. Metformin in COVID-19: A possible role beyond diabetes.
32339534 2020. COVID-19 and diabetes: Is metformin a friend or foe?
DPP4
32333972 ä. Letter to the Editor in response to the article ?COVID-19 and diabetes: Can DPP4 inhibition play a role??
32333966 2020. COVID-19 and diabetes: Is this association driven by the DPP4 receptor? Potential clinical and therapeutic implications
32333969 ä. Response to COVID -19 and Diabetes: Can DPP4 Inhibition Play a Role? ? GLP-1 Might Play One Too
32283128 ä. Should anti-diabetic medications be reconsidered amid COVID-19 pandemic? on ace2 via adam17, nfkb via dpp4
32061923 2020. Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions
32349031 2020. Role of Dipeptidyl Peptidase 4 Inhibitors in Diabetic Patients with Coronavirus-19 Infection
32336007 2020. DPP4 inhibition: preventing SARS-CoV-2 infection and/or progression of COVID-19?
32224164 2020. COVID-19 and diabetes: Can DPP4 inhibition play a role?
32335097 2020. SARS-CoV-2 and DPP4 inhibition: Is it time to pray for Janus Bifrons?
32416120 2020. Is DPP4 inhibition a comrade or adversary in COVID-19 infection.
SGLT2
32335366 2020. Can dapagliflozin have a protective effect against COVID-19 infection? A hypothesis
32447736 2020. Lack of Efficacy of SGLT2-i in Severe Pneumonia Related to Novel Coronavirus (nCoV) Infection: No Little Help from Our Friends.
PPAR
32344313 ä. Can pioglitazone be potentially useful therapeutically in treating patients with covid-19?
32365556 2020. Pharmacological (or Synthetic) and Nutritional Agonists of PPAR-gamma as Candidates for Cytokine Storm Modulation in COVID-19 Disease
32334392 2020. Enhancing immunity in viral infections, with special emphasis on COVID-19: A review.
32234504 2020. COVID-19, diabetes mellitus and ACE2: The conundrum.
